Fidelity Investments’s ProQR Therapeutics PRQR Stock Holding History

Fidelity Investments’s Portfolio PRQR Stock Details PRQR Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-1	Closed	–	–	5368
2022 Q1	$0	Sell	1 -4,462,437	-100%	-$14.9M	﹤0.01%	5370
2021 Q4	$35.7M	Sell	4,462,438 -330,835	-7%	-$2.52M	﹤0.01%	1565
2021 Q3	$40.1M	Buy	4,793,273 +41,874	+0.9%	+$274K	﹤0.01%	1511
2021 Q2	$32M	Sell	4,751,399 -534	-0%	-$3.44K	﹤0.01%	1636
2021 Q1	$31.4M	Buy	4,751,933 +4,651,517	+4,632%	+$23.8M	﹤0.01%	1597
2020 Q4	$422K	Sell	100,416 -25,500	-20%	-$108K	﹤0.01%	2677
2020 Q3	$603K	Sell	125,916 -354,700	-74%	-$1.86M	﹤0.01%	2512
2020 Q2	$2.92M	Sell	480,616 -409,600	-46%	-$2.21M	﹤0.01%	2193
2020 Q1	$4.89M	Sell	890,216 -289,270	-25%	-$2.22M	﹤0.01%	1946
2019 Q4	$11.7M	Buy	1,179,486 +401,300	+52%	+$3.13M	﹤0.01%	1793
2019 Q3	$4.48M	Hold	778,186	–	–	﹤0.01%	2088
2019 Q2	$7.08M	Sell	778,186 -180,100	-19%	-$2.12M	﹤0.01%	1994
2019 Q1	$13.3M	Sell	958,286 -123,080	-11%	-$1.84M	﹤0.01%	1756
2018 Q4	$17.1M	Buy	1,081,366 +235,053	+28%	+$4.31M	﹤0.01%	1623
2018 Q3	$16.4M	Buy	846,313 +608,397	+256%	+$6.47M	﹤0.01%	1766
2018 Q2	$1.74M	Hold	237,916	–	–	﹤0.01%	2364
2018 Q1	$732K	Hold	237,916	–	–	﹤0.01%	2478
2017 Q4	$767K	Hold	237,916	–	–	﹤0.01%	2475
2017 Q3	$1.15M	Hold	237,916	–	–	﹤0.01%	2398
2017 Q2	$1.24M	Hold	237,916	–	–	﹤0.01%	2408
2017 Q1	$1.19M	Hold	237,916	–	–	﹤0.01%	2427
2016 Q4	$1.17M	Hold	237,916	–	–	﹤0.01%	2451
2016 Q3	$1.59M	Hold	237,916	–	–	﹤0.01%	2402
2016 Q2	$1.15M	Hold	237,916	–	–	﹤0.01%	2455
2016 Q1	$1.16M	Sell	237,916 -2,021,885	-89%	-$10.3M	﹤0.01%	2459
2015 Q4	$19.6M	Hold	2,259,801	–	–	﹤0.01%	1703
2015 Q3	$32.9M	Hold	2,259,801	–	–	﹤0.01%	1430
2015 Q2	$37.7M	Buy	2,259,801 +38,486	+2%	+$725K	﹤0.01%	1462
2015 Q1	$48.6M	Buy	2,221,315 +2,148,715	+2,960%	+$44.4M	0.01%	1343
2014 Q4	$1.57M	Hold	72,600	–	–	﹤0.01%	2464
2014 Q3	$1.25M	Buy	+72,600	New	+$1.16M	﹤0.01%	2509

Other funds holding PRQR

PFM

Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return

Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return

Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return

MCM

M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

MAM

Monaco Asset Management Monaco $542M AUM 54.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Fidelity Investments's PRQR Position: Q2 2022 in Review

Fidelity Investments sold out of ProQR Therapeutics (PRQR) in Q2 2022, closing a stake of 1 share.

Fidelity Investments first reported a position in PRQR in Q3 2014 and held it in 31 quarters. The position peaked at $48.6M in Q1 2015. 51 funds tracked by Wall St. Rank hold PRQR as of Q2 2022.

Fidelity Investments reported no remaining ProQR Therapeutics position as of Q2 2022 after selling out during the quarter.
Fidelity Investments sold 1 ProQR Therapeutics share in Q2 2022.
Fidelity Investments first reported a position in ProQR Therapeutics in Q3 2014 and held it in 31 quarters.
Fidelity Investments's ProQR Therapeutics position peaked at $48.6M in Q1 2015.
51 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q2 2022.

Based on Fidelity Investments's 13F filing for Q2 2022, filed 12 Aug 2022.